Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantAetna Heart-Lung Transplant Coverage & Prior Auth …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0597

    Heart-Lung Transplantation

    Customize your policy alerts

    Sign up for Aetna Policy 0597 alerts

    Get alerted when Policy 0597 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity criteria for heart-lung transplantation for Aetna members with severe refractory heart failure combined with end-stage lung disease or irreversible pulmonary hypertension, and related coding and background information for providers and transplant centers.

    Policy Summary
    PayerAetna
    PolicyHeart-Lung Transplantation
    Policy CodePolicy 0597
    Change TypeNo material change
    Effective DateMar 12, 2002
    Last ReviewSep 7, 2023
    Next Review DateJun 27, 2024
    Key ActionObtain prior authorization for heart-lung transplantation procedures when selection criteria are met and no absolute contraindications are present.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    33930-33945Covered CPT range

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    E84.0-J47.9
    Representative ICD-10
    NYHA III/IVSeverity threshold
    Bili<2.5; CrCl>50Liver/kidney reqs
    CD4>200HIV control
    06/27/2024Next review

    Coverage and Medical Necessity Criteria

    Medical necessity criteria

    Covered when ALL of the following are met

    Primary indication: Severe refractory heart failure plus end-stage lung disease or irreversible pulmonary hypertensionNYHA III or IV as example

    Examples include COPD with severe heart failure; congenital heart disease with pulmonary hypertension not amenable to repair; cystic fibrosis with severe heart failure; Eisenmenger’s complex; irreversible primary pulmonary hypertension; connective tissue disease with severe pulmonary fibrosis and uncontrollable pulmonary hypertension; severe coronary artery disease or cardiomyopathy with irreversible pulmonary hypertension

    Selection criteria (recipient factors): Absence of chronic high-dose steroid therapy; absence of acute or chronic active infections that are not effectively treated; absence of active malignancy unless completely resected or judged to have low likelihood of recurrence; adequate functional status (active rehabilitation; mechanically ventilated or immobile persons are generally poor candidates unless bridged with ambulatory ECMO); adequate liver and kidney function (bilirubin < 2.5 mg/dL; creatinine clearance > 50 ml/min/kg); life expectancy > 2 years in the absence of cardiopulmonary disease; no active alcohol or chemical dependency; no uncontrolled or untreated psychiatric disorders that interfere with compliance; HIV, if present, under adequate control (CD4 > 200 cells/mm3 for >6 months, undetectable HIV-1 RNA, on stable antiretroviral therapy >3 months, and no AIDS-related complications)see detailed thresholds

    Member must also meet the transplanting institution's selection criteria; bridge to transplant with ambulatory ECMO does not by itself rule out candidacy

    Contraindications / Not medically necessary

    Not medically necessary when ANY of the following absolute contraindications are present

    Absolute contraindications: Irreversible end‑organ disease (e.g., renal, hepatic); active malignancy or infections; systemic diseases (autoimmune, vascular, amyloidosis); chronic gastrointestinal disease (e.g., bleeding peptic ulcer, diverticulitis, active or recurrent pancreatitis); progressive neuromuscular disease; use of tobacco products (ongoing tobacco use); untreated or unstable cerebrovascular disease; uncontrolled psychiatric disorders; multi‑system diseases that significantly affect outcomes; other conditions where risks of transplantation exceed benefitsN/A

    Under established guidelines, obese (>20% of ideal body weight), cachectic (<80% of ideal body weight), mechanically ventilated or otherwise immobile patients are considered poor candidates and may be considered not medically necessary

    Heart-lung transplantation is indicated when a patient has severe refractory heart failure plus end-stage lung disease or irreversible pulmonary hypertension and meets the selection criteria described in this policy. Examples include cystic fibrosis with severe heart failure, Eisenmenger’s complex, irreversible primary pulmonary hypertension, connective tissue disease with severe pulmonary fibrosis and uncontrollable pulmonary hypertension, and severe coronary artery disease or cardiomyopathy with irreversible pulmonary hypertension. Heart-lung transplantation is not medically necessary where lung transplantation alone would restore right ventricular function; every attempt should be made to preserve the heart.

    This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is intended to assist in administering benefits. It does not constitute a contract, guarantee coverage, or provide medical advice. Coverage determinations remain subject to the terms of the member’s benefit plan and any applicable medical necessity criteria described herein; providers are responsible for confirming eligibility and benefit coverage.

    Certain recipient factors are associated with poor outcomes and are considered ineligibility risks. Under established guidelines, patients who are obese (greater than 20% of ideal body weight), cachectic (less than 80% of ideal body weight), or who are mechanically ventilated or otherwise immobile are considered poor candidates for transplantation unless specific mitigating circumstances exist (for example, ambulatory ECMO as a bridge may be evaluated). These factors may render the procedure not medically necessary.

    Coding and Diagnostic Criteria

    Covered CPT CodesCPTCovered
    33930-33945Heart/lung transplant
    Covered HCPCS CodesHCPCSCovered
    S2054Transplantation of multivisceral organs
    S2055Harvesting of donor multivisceral organs, with preparation and maintenance of allografts; from cadaver donor
    S2060Lobar lung transplantation
    S2061Donor lobectomy (lung) for transplantation, living donor
    Covered ICD-10 CodesICD-10Covered
    E84.0-E84.9Cystic fibrosis
    I25.10-I25.9Chronic ischemic heart disease
    I26.01-I127.9Pulmonary heart disease
    I42.0-I43Cardiomyopathy
    I50.1-I50.9Heart failure
    J40-J47.9Chronic lower respiratory diseases
    J84.10Pulmonary fibrosis, unspecified
    J84.89Other specified interstitial pulmonary diseases
    M32.0-M35.9Diffuse diseases of connective tissue
    Q20.0-Q28.9Congenital malformations of the circulatory system
    1–10 of 13
    1/2
    inv-09: Liver and kidney function — bilirubin and creatinine clearance thresholds
    Total bilirubin threshold< 2.5 mg/dL
    Creatinine clearance threshold> 50 ml/min/kg
    ContextAdequate liver and kidney function required as part of candidate selection
    inv-10: Life expectancy (without cardiopulmonary disease) — > 2 years
    Life expectancy requirement> 2 years (in the absence of cardiopulmonary disease)
    ContextRequired as part of recipient physiologic and comorbidity assessment

    Candidate Selection Criteria

    Candidate selection criteria

    Candidate must meet institution selection criteria or the following Aetna criteria:

    Clinical indication: Severe refractory heart failure plus end-stage lung disease or irreversible pulmonary hypertensionNYHA III or IV or equivalent severity

    Policy examples include cystic fibrosis with severe heart failure, Eisenmenger's complex, irreversible primary pulmonary hypertension, connective tissue disease with severe pulmonary fibrosis

    Physiologic and comorbidity requirements: Absence of chronic high-dose steroids; absence of acute or chronic active infections that are not effectively treated; absence of active malignancy unless completely resected or deemed low recurrence risk; adequate functional status with active rehabilitation (mechanically ventilated or immobile persons are generally poor candidates though ambulatory ECMO bridge is not an absolute exclusion); adequate liver and kidney function (bilirubin < 2.5 mg/dL; creatinine clearance > 50 ml/min/kg); life expectancy > 2 years absent cardiopulmonary disease; abstinence from smoking for at least 3 months; no active alcohol or chemical dependency; no uncontrolled psychiatric disorders; controlled HIV if present (CD4 >200 cells/mm3 for >6 months, undetectable viral load, on stable ART >3 months, and no AIDS complications)

    Contraindications

    Absolute contraindications that generally render heart-lung transplantation not medically necessary include irreversible end‑organ disease (for example, renal or hepatic failure), active malignancy or active infection, and significant systemic diseases such as autoimmune or vascular disorders and amyloidosis. Chronic gastrointestinal conditions (for example, bleeding peptic ulcer, diverticulitis, active or recurrent pancreatitis), progressive neuromuscular disease, uncontrolled psychiatric disorders, and ongoing tobacco use are additional contraindications. The presence of significant multi‑system disease that is expected to adversely affect outcomes also argues against transplantation.

    Pre-Transplant Evaluation Requirements

    Documentation Required

    Comprehensive pre‑transplant evaluation required

    Perform a comprehensive pre-transplant evaluation documenting severity of cardiac and pulmonary disease, and objective organ function measures (liver and kidney). Evaluation must address infection and malignancy status, functional status and rehabilitation potential, and HIV control if applicable.

    • Assess heart failure severity (e.g., NYHA III–IV) and confirm end-stage lung disease or irreversible pulmonary hypertension [[see policy examples]].
    • Document liver and kidney function: bilirubin < 2.5 mg/dL and creatinine clearance > 50 ml/min/kg.
    • Evaluate for active or chronic infections and malignancy; ensure adequate functional/rehabilitation status and address HIV control if present (CD4 >200, undetectable viral load, stable ART >3 months).

    Provider Actions and Prior Authorization

    Prior Authorization

    Prior authorization required for heart‑lung transplant procedures

    Obtain prior authorization before performing heart‑lung transplantation procedures (covered CPT codes 33930–33945 and related HCPCS S2054, S2055, S2060, S2061) when the member meets selection criteria and no absolute contraindications are present.

    • Submit documentation that selection criteria are met and contraindications are absent as part of the authorization request.
    Note

    No separate prior authorization code list provided

    No additional explicit prior authorization codes or separate prior authorization requirement language is provided in the policy beyond the listed transplant procedure codes and HCPCS codes.

    • Refer to the procedure and HCPCS codes listed elsewhere in the policy for authorization submissions.

    Transplant Center Requirements

    Step Therapy

    Must meet transplanting institution’s selection criteria

    Member must meet the transplanting institution’s selection criteria; if the institution has no criteria, ensure the patient meets all Aetna selection criteria before listing.

    • When institutional criteria are absent, document that all Aetna criteria are met (clinical indication, organ function thresholds, functional status, absence/control of contraindications).
    • Consider referral to an experienced transplant center that meets institutional selection standards.

    Post-Transplant Surveillance and References

    inv-27: Post-transplant surveillance and management — clinical guidance only in background about complications and chronic rejection
    Primary post‑op complications (early)Acute isolated lung rejection, multi-organ failure, bacterial pneumonia (within first postoperative month)
    Late post‑op complicationsViral pneumonia, fungal infection, tuberculosis, chronic obliterative bronchiolitis (chronic rejection)
    Clinical guidance roleBackground discussion only — anticipatory management and surveillance recommended but no explicit coverage rules provided
    inv-28: Reference literature — references for indications, outcomes, techniques, and considerations (35+ refs)
    Scope of referencesLiterature covers indications, outcomes, techniques, and considerations for heart‑lung transplantation
    Number of citations

    Background and Scope

    Heart-lung transplantation is used for patients whose disease combines severe refractory heart failure and end-stage lung disease or irreversible pulmonary hypertension, where single-organ transplantation would not adequately restore cardiopulmonary function. The procedure is historically applied to conditions such as congenital heart disease with pulmonary hypertension, cystic fibrosis with severe cardiac involvement, primary pulmonary hypertension, and selected cases of connective tissue disease with severe pulmonary fibrosis. Donor organ availability limits procedure frequency, and post-operative complications include early events such as acute lung rejection and multi-organ failure, and later complications such as infection and chronic obliterative bronchiolitis.

    The information in this bulletin is informational and does not replace the member’s benefit contract. It is not an explicit coverage guarantee or a substitute for individualized clinical judgment; providers should consult the member’s plan documents and authorizations for coverage specifics.

    Definitions

    inv-22: NYHA classification — NYHA functional class I–IV definitions
    NYHA Class ICardiac disease without limitation of physical activity; ordinary activity does not cause symptoms
    NYHA Class IISlight limitation of physical activity; comfortable at rest; ordinary activity causes symptoms
    NYHA Class IIIMarked limitation of physical activity; comfortable at rest; less than ordinary activity causes symptoms
    NYHA Class IVInability to carry on any physical activity without discomfort; symptoms may be present at rest

    Policy History and Review Dates

    Policy effective date: 03/12/2002. Last review: 09/07/2023. Next scheduled review: 06/27/2024. This policy’s review history and revisions are documented in the policy history file.

    Policy Summary
    PayerAetna
    PolicyHeart-Lung Transplantation
    Policy CodePolicy 0597
    Change TypeNo material change
    Effective DateMar 12, 2002
    Last ReviewSep 7, 2023
    Next Review DateJun 27, 2024
    Key ActionObtain prior authorization for heart-lung transplantation procedures when selection criteria are met and no absolute contraindications are present.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding and Diagnostic CriteriaCandidate Selection CriteriaContraindicationsPre-Transplant Evaluation RequirementsProvider Actions and Prior AuthorizationTransplant Center RequirementsPost-Transplant Surveillance and ReferencesBackground and ScopeDefinitionsPolicy History and Review Dates
    Role in selectionUsed to ensure anticipated non-cardiopulmonary survival sufficient to benefit from transplant
    inv-11: HIV control parameters — CD4, viral load, ART stability
    CD4 count> 200 cells/mm3 for more than 6 months
    Viral loadHIV-1 RNA undetectable
    Antiretroviral therapy stabilityOn stable antiretroviral therapy for > 3 months
    AIDS complicationsNo other complications from AIDS (opportunistic infections or AIDS-related neoplasms)
    inv-12: NYHA class — Class III or IV considered severe
    Severe NYHA classesClass III or IV considered severe for selection
    Class III definitionMarked limitation of physical activity; comfortable at rest; less than ordinary activity causes symptoms
    Class IV definitionInability to carry on any physical activity without discomfort; symptoms may be present at rest
    see thresholds

    Member must meet the transplanting institution's selection criteria if available

    Note
    Note
    Documentation Required

    Required clinical documentation to support medical necessity

    Include clinical documentation demonstrating severe refractory heart failure plus end‑stage lung disease or irreversible pulmonary hypertension and that the candidate meets listed selection criteria (NYHA class, organ function thresholds, absence/control of infection or malignancy, functional status, and HIV control when applicable).

    • Document NYHA class (III or IV) or equivalent severity and examples/diagnoses supporting indication.
    • Provide lab values showing bilirubin < 2.5 mg/dL and creatinine clearance > 50 ml/min/kg.
    • If HIV positive, include CD4 > 200 cells/mm3 for >6 months, undetectable viral load, and evidence of stable antiretroviral therapy >3 months.
    Note

    Policy history — no additional provider actions specified

    Policy history and review dates are provided for reference; these chunks do not specify extra provider steps or documentation beyond the clinical and authorization requirements in the policy.

    • Last review: 09/07/2023. Effective: 03/12/2002. Next review: 06/27/2024.
    Denial Risk

    Absolute contraindications may cause denial of coverage

    Be aware that the presence of absolute contraindications may render transplantation not medically necessary and can lead to coverage denial.

    • Absolute contraindications include irreversible end‑organ disease (renal, hepatic), active malignancy or infection, systemic diseases (autoimmune/vascular/amyloidosis), chronic GI disease, progressive neuromuscular disease, uncontrolled psychiatric disorders, active substance dependence, and ongoing tobacco use.
    • Obesity >20% of ideal body weight, cachexia <80% of ideal body weight, mechanical ventilation or immobility are considered poor candidates and may affect coverage decisions.
    Note

    No specific provider actions listed in this section

    No provider‑action requirements are specified in these policy chunks.

    35+ references cited in the policy reference list
    Representative sourcesPeer‑reviewed surgical and transplant series, guidelines, and systematic reviews (e.g., J Thorac Cardiovasc Surg; Clin Chest Med; UpToDate)